Trials / Conditions / Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

11 registered clinical trials studyying Esophagogastric Adenocarcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma NCT07507968	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Recruiting	Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for NCT06731803	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 1 / Phase 2
Recruiting	A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer NCT06623396	Memorial Sloan Kettering Cancer Center	Phase 1
Completed	Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinom NCT06123468	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 1 / Phase 2
Active Not Recruiting	Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophago NCT05504720	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Completed	Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative NCT05268510	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Phase 2
Recruiting	Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study NCT04219137	University Health Network, Toronto	—
Completed	Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma NCT03921021	Weill Medical College of Cornell University	Phase 2
Completed	Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma NCT03193918	Arog Pharmaceuticals, Inc.	Phase 1
Withdrawn	Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) NCT02856867	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2
Completed	Nintedanib in Patients With Advanced Esophagogastric Cancer NCT02234596	Memorial Sloan Kettering Cancer Center	Phase 2